CDH2 and melanoma: Given the differential effect of the PKC inhibitors Gö6976 and Gö6983, our present data suggest that specific isoenzyme(s) targeted by Gö6976 but not by Gö6983 would be involved in the reversion of the E- to N-cadherin switch and metastatic phenotype in melanoma.